Shares of Smith & Nephew plc (NYSE:SNN) have earned an average rating of “Hold” from the eight research firms that are currently covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company.
A number of equities research analysts recently commented on the stock. JPMorgan Chase & Co. lowered shares of Smith & Nephew from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 1st. Zacks Investment Research lowered shares of Smith & Nephew from a “hold” rating to a “sell” rating in a report on Thursday, September 27th. Canaccord Genuity reiterated a “buy” rating on shares of Smith & Nephew in a report on Thursday, November 1st. HSBC lowered shares of Smith & Nephew from a “buy” rating to a “hold” rating in a report on Tuesday, October 16th. Finally, Morgan Stanley upgraded shares of Smith & Nephew from an “equal weight” rating to an “overweight” rating in a report on Monday, December 10th.
Shares of SNN traded down $0.29 during mid-day trading on Tuesday, reaching $37.68. The company’s stock had a trading volume of 797,100 shares, compared to its average volume of 804,593. The firm has a market cap of $16.61 billion, a price-to-earnings ratio of 19.82, a PEG ratio of 3.26 and a beta of 0.49. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 2.13. Smith & Nephew has a 52 week low of $32.22 and a 52 week high of $39.85.
Smith & Nephew Company Profile
Smith & Nephew Plc engages in the development, manufacture, marketing, and sale of medical devices. It offers the following products and services: sports medicine joint repair; arthroscopic enabling technologies; trauma and extremities; other surgical businesses; knee and hip implants, and advanced wound care, wound bioactives, and wound devices.
Featured Story: Liquidity
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.